Latest news with #ADCs
Yahoo
4 hours ago
- Business
- Yahoo
Akari Therapeutics Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Video webcast now available on-demand BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Gaslightwala dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Presentations page in the Investors section of the Company's website ( About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload. For more information about the Company, please visit and connect on X and LinkedIn. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 AKTX@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
a day ago
- Business
- Business Standard
Anthem Biosciences jumps on debut
Shares of Anthem Biosciences were currently trading at Rs 726.35 at 10:21 IST on the BSE, representing a premium of 27.43% compared with the issue price of Rs 570. The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price. So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far. The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Yahoo
4 days ago
- Business
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Standard
5 days ago
- Business
- Business Standard
Anthem Biosciences IPO ends with 63.86x subscription
The offer received bids for 281.45 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,45,24,128 shares as against 4,40,70,682 shares on offer. The issue was subscribed 63.86 times. The Qualified Institutional Buyers (QIBs) category was subscribed 182.65 times. The Non-Institutional Investors (NIIs) category was subscribed 42.36 times. The Retail Individual Investors (RIIs) category was subscribed 5.64 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
6 days ago
- Business
- Business Standard
Anthem Biosciences IPO subscribed 63.86 times
The offer received bids for 281.44 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,44,34,740 shares as against 4,40,70,682 shares on offer, according to stock exchange data at 17:30 IST on Wednesday (16 July 2025). The issue was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
